ReviewIranian journal of pathology2026
Evaluation of CD10 Expression in Endometrial Carcinoma: A Systematic Review.
Review in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: CD10 is a membrane-bound metalloproteinase that plays a role in tumor progression and differentiation. Its diagnostic significance in endometrial carcinoma, especially in distinguishing between histological subtypes and invasion patterns, is still being studied. This systematic review aims to compile evidence on CD10 expression in endometrial carcinoma, focusing on its prevalence, staining patterns, and correlations with clinicopathological features. Methods: A comprehensive search was conducted across PubMed, Scopus, and Embase in March 2025, yielding 17 eligible studies. Data on CD10 expression, histological subtypes, staining localization, and associations with tumor grade, stage, and diagnostic utility were qualitatively synthesized. The Newcastle-Ottawa Scale was used to assess the quality of the studies. Results: CD10 expression was predominantly observed in the stromal compartment of endometrioid carcinomas, with a periglandular or "fringe-like" pattern. Stromal expression levels were consistently high, whereas epithelial expression varied significantly. An inverse correlation between CD10 expression and tumor grade was observed, with lower expression in higher-grade tumors. The role of CD10 in differentiating myoinvasion from adenomyosis was limited, as both conditions exhibited overlapping staining patterns. Luminal epithelial staining in mesonephric-like adenocarcinomas was not exclusive, further complicating its diagnostic value. Conclusion: CD10 is a useful marker of stromal tissue in endometrial carcinoma and may aid in distinguishing histological patterns and mimics. However, its diagnostic and prognostic value is constrained by nonstandardized methods and overlapping expression profiles. Standardizing IHC protocols and conducting large-scale studies are essential to enhance CD10's clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.